UniQure Revenue 2013-2022 | QURE
UniQure revenue from 2013 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
UniQure Annual Revenue
(Millions of US $) |
| 2022 |
$106 |
| 2021 |
$524 |
| 2020 |
$38 |
| 2019 |
$7 |
| 2018 |
$11 |
| 2017 |
$13 |
| 2016 |
$25 |
| 2015 |
$11 |
| 2014 |
$6 |
| 2013 |
$4 |
| 2012 |
$ |
UniQure Quarterly Revenue
(Millions of US $) |
| 2022-12-31 |
|
| 2022-09-30 |
$1 |
| 2022-06-30 |
$0 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$58 |
| 2021-09-30 |
$2 |
| 2021-06-30 |
$464 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$34 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$3 |
| 2018-06-30 |
$3 |
| 2018-03-31 |
$3 |
| 2017-12-31 |
$3 |
| 2017-09-30 |
$2 |
| 2017-06-30 |
$5 |
| 2017-03-31 |
$3 |
| 2016-12-31 |
$9 |
| 2016-09-30 |
$7 |
| 2016-06-30 |
$4 |
| 2016-03-31 |
$4 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$2 |
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2012-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.943B |
$0.106B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
